| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a92803f6cf472da3edb056e6ddcf5fb5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 |
| filingDate |
2006-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8cb703f55bd9a7bd9d1fb190c8603bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76321e8b4308eb4c22478e23e74e5be3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21078ccfdf280d10a732d8babb3d3704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23eaaf49aae8cb480e90322206dd8da4 |
| publicationDate |
2010-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
NZ-561338-A |
| titleOfInvention |
High affinity HIV T cell receptors |
| abstract |
Provided is a T-cell receptor (TCR) having the property of binding to SLYNTVATLHLA- A*0201 and comprising at least one TCR alpha chain variable domain and/or at least one TCR beta chain variable domain wherein (i) the TCR a chain variable domain has a specified sequence except that at least one complementarity determining region thereof is/are mutated and/or the TCR alpha chain variable domain has a specified sequence except that at least one complementarity determining region thereof is/are mutated; and (ii) the TCR has a KD for the said SLYNTVATL-HLA-A*0201 complex of less than or equal to 1 micromole and/or has an off-rate (koff) for the SLYNTVATL-HLA-A*0201 complex of 1 x 10-3s-1 or slower. Further provided are corresponding pharmaceutical compositions. |
| priorityDate |
2005-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |